Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innoviva (INVA) Gains from Sales and Divestitures (2009 - 2025)

Innoviva posted quarterly Gains from Sales and Divestitures of $300000.0 for Q4 2025, up 24.48% year-on-year from $241000.0 in Q4 2024, and up 24.48% on a QoQ basis from $241000.0 in Q4 2024.

Innoviva (INVA) has 17 years of Gains from Sales and Divestitures data on file, last reported at $300000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 24.48% year-over-year to $300000.0; the trailing twelve-month figure through Dec 2025 stood at $300000.0 (up 24.48% YoY), and the FY2025 full-year result was $300000.0, up 24.48% from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 stood at $300000.0, up from $241000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $300000.0 in Q4 2025 and bottomed at $86.0 in Q4 2021.
  • The 5-year median for Gains from Sales and Divestitures is $241000.0 (2024), against an average of $211617.2.
  • The widest annual swing landed in 2021, when Gains from Sales and Divestitures plunged 99.69%; it then surged 270830.23% in 2022.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $86.0 in 2021, then soared by 270830.23% to $233000.0 in 2022, then rose by 21.89% to $284000.0 in 2023, then dropped by 15.14% to $241000.0 in 2024, then advanced by 24.48% to $300000.0 in 2025.
  • The last three Gains from Sales and Divestitures figures came in at $300000.0 (Q4 2025), $241000.0 (Q4 2024), and $284000.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 300,000.00
Dec 31, 2025 300,000.00
Dec 31, 2024 241,000.00
Dec 31, 2024 241,000.00
Dec 31, 2023 284,000.00
Dec 31, 2023 284,000.00
Dec 31, 2022 233,000.00
Dec 31, 2022 233,000.00
Dec 31, 2021 86.00
Dec 31, 2021 86.00
Dec 31, 2020 28,000.00
Dec 31, 2020 28,000.00
Dec 31, 2019 92,000.00
Dec 31, 2019 92,000.00
Dec 31, 2018 444,000.00
Dec 31, 2018 444,000.00
Dec 31, 2017 412,000.00
Dec 31, 2017 412,000.00
Dec 31, 2016 809,000.00
Dec 31, 2016 809,000.00
Dec 31, 2015 883,000.00
Dec 31, 2015 883,000.00
Dec 31, 2014 538,000.00
Dec 31, 2014 538,000.00
Dec 31, 2013 630,000.00
Dec 31, 2013 630,000.00
Dec 31, 2012 388,000.00
Dec 31, 2012 388,000.00
Dec 31, 2011 63,000.00
Dec 31, 2011 63,000.00
Dec 31, 2010 24,000.00
Dec 31, 2010 24,000.00
Dec 31, 2009 603,000.00
Dec 31, 2009 603,000.00